Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
Cancer Science · 2024-12 · 115 (12) · 3986-3996
DOI: 10.1111/cas.16335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 25.09.2024. Verfasst von Ryo Tsumura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan. Hauptthemen laut MEDLINE: Oligopeptides, Pancreatic Neoplasms, Immunoconjugates, Thromboplastin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Center Research and Development Fund, Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have been recognized as a promising class of cancer therapeutics. Tissue factor (TF), an initiator of the blood coagulation pathway, has been investigated regarding its relationship with cancer, and several preclinical and clinical studies have presented data on anti‐TF ADCs, including tisotumab vedotin, which was approved in 2021. However, the feasibility of other payloads in the design of anti‐TF ADCs is still unclear because no reports have compared payloads with different cytotoxic mechanisms. For ADCs targeting other antigens, such as Her2, optimizing the payload is also an important issue in order to improve in vivo efficacy. In this study, we prepared humanized anti‐TF Ab (clone.1084) conjugated with monomethyl auristatin E (MMAE) or deruxtecan (DXd), and evaluated the efficacy in several cell line‐ and patient‐derived xenograft models of pancreatic cancer. As a result, optimizing the drug / Ab ratio was necessary for each payload in order to prevent pharmacokinetic deterioration and maximize delivery efficiency. In addition, MMAE‐conjugated anti‐TF ADC showed higher antitumor effects in tumors with strong and homogeneous TF expression, while DXd‐conjugated anti‐TF ADC was more effective in tumors with weak and heterogeneous TF expression. Analysis of a pancreatic cancer tissue array showed weak and heterogeneous TF expression in most TF‐positive specimens, indicating that the response rate to pancreatic cancer might be higher for DXd‐ than MMAE‐conjugated anti‐TF ADC. Nevertheless, our findings indicated that optimizing the ADC payloads individually in each patient could maximize the potential of ADC therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Developmental Therapeutics, EPOC, National Cancer Center, Kashiwa, Japan.
- Department of Chemistry and Materials Science, National Institute of Technology (KOSEN), Gunma College, Maebashi, Japan.
- Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
- Research Division, RIN Institute Inc., Tokyo, Japan.
ORCID-Profile: Ryo Tsumura, Yoshikatsu Koga, Hiroki Takashima, Yasuhiro Matsumura, Masahiro Yasunaga
Förderung
- National Cancer Center Research and Development Fund
- Japan Society for the Promotion of Science
- Takeda Science Foundation
Zitieren
APA
Tsumura, R., Anzai, T., Koga, Y., Takashima, H., Matsumura, Y., & Yasunaga, M. (2024). Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. Cancer Science, 115(12), 3986-3996. https://doi.org/10.1111/cas.16335
Vancouver
Tsumura R, Anzai T, Koga Y, Takashima H, Matsumura Y, Yasunaga M. Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. Cancer Science. 2024;115(12):3986-3996. doi:10.1111/cas.16335
BibTeX
@article{Tsumura2024,
author = {Tsumura, Ryo and Anzai, Takahiro and Koga, Yoshikatsu and Takashima, Hiroki and Matsumura, Yasuhiro and Yasunaga, Masahiro},
title = {Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {12},
pages = {3986--3996},
doi = {10.1111/cas.16335}
}
EUVIMED